MarginsXMarginsX
Home › Markets › Health Care › CNTN

Canton Strategic Holdings Inc. (CNTN)

CNTN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.64
-4.09% on the day
Market cap
$130.7M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCNTN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001861657
SEC industry codeFinance Services
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
20.2 months
$37.2M cash at June 30, 2026
Share count, 1 year
+1619.0%
2025-08-11 to 2026-08-13 · +170327.9% over 3 years
Going-concern doubt
No
10-Q filed August 14, 2026
Insider net buying, 12 months
-$258K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-14
Cash and burn$37.2M cash; operating cash flow -$5.5M a quarter.Report 2026-06-30
Shares outstanding79,681,361 (2026-08-13); 4,635,251 a year earlier; 17,532,637 three years earlier. 3y figure adjusted for splits (1-for-375 overall).Cover page 2026-08-13
Reverse splits, 3 years2; latest 1-for-15 on 2024-05-28Source 2024-05-28
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-03-03
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-01-15
AuditorRosenberg Rich Baker Berman, P.A., Somerset, New Jersey, United StatesPCAOB Form AP 2026-04-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $258K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$1.5M-$19.3M-$2.2M$37.2MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$47.3M-$7.6M$41.5MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2025
2025-12-31
Not filed-$29.4M-$10.4M$12.0MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$2.1M-$1.9M$7.6M$322KNeeds four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
Not filed-$1.9M-$1.1M$2.2M$499KNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$2.5M-$2.7M$1.1M$543KNeeds four quarters10-Q 2026-05-13
Q4 2024
2024-12-31
Not filed-$3.8M-$3.0M$3.6MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$3.8M-$2.9M$4.8MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-03
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEF 14A2026-06-25

Source: SEC EDGAR submissions feed, 320 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-17.0%
1 month-15.3%
3 months-13.2%
Year to date-43.6%
1 year-43.2%
From 52-week high-68.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
MENSJyong Biotech Ltd.$1.77+0.57%$134.6M
ALXOALX Oncology Holdings Inc.$1.00-3.85%$124.9M
AKBAAkebia Therapeutics Inc.$0.4486-5.40%$124.6M
MSLESatellos Bioscience Inc.$6.47-2.34%$137.3M
MGNXMacroGenics Inc.$2.17-1.36%$138.7M
RNAAtrium Therapeutics Inc.$6.43-14.38%$138.7M
SPRBSpruce Biosciences Inc.$42.25-2.45%$121.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier